Mesabi Trust（MSB）資訊與事件

$24.620

-0.069 (-0.28%)收盤時

MSB 資訊

8.507-30Globenewswire

Mesoblast Advances Ryoncil® for Inflammatory Diseases

9.504-30moomoo

Mesoblast Announces RYONCIL® Net Revenues of $30.3 Million and Reduced Net Operating Cash Expenditure of $4.1 Million for the Quarter

9.004-08moomoo

MESOBLAST GETS FDA IND APPROVAL TO INITIATE REGISTRATIONAL TRIAL FOR RYONCIL

9.004-08moomoo

MESOBLAST LTD - FDA Approves RYONCIL IND for DMD Registration Trial

9.504-07moomoo

MESOBLAST LTD - RYONCIL QUARTERLY NET REVENUE RISES TO US$30.3M

2.003-13CNBC

Market Dynamics and Corporate Changes

8.001-19seekingalpha

Mesabi Trust (MSB) Declares $0.26 Quarterly Dividend Payable February 20

9.001-19NASDAQ.COM

Mesoblast Receives FDA Feedback for BLA Filing of rexlemestrocel-L

9.501-09Globenewswire

Mesoblast Reports 60% Revenue Growth to $35.1 Million in Q4

5.001-01Globenewswire

Mesoblast Appoints New Chair to Drive Commercialization Efforts

查看更多資訊

MSB 事件

1/2 05:10

Mesoblast Appoints Philip Facchina as New Non-Executive Chair

Mesoblast announced that Jane Bell will retire from her role as chair and will remain on the board as a non-executive director. The board has unanimously appointed Philip Facchina to the role of non-executive chair. Facchina joined the Mesoblast board in March 2021.

10/17 16:06

Mesabi Trust raises quarterly distribution to 39c per share from 35c

The Trustees of Mesabi Trust declared a distribution of 39c per Unit of Beneficial Interest payable on November 20, 2024 to Mesabi Trust Unitholders of record at the close of business on October 30, 2024. This compares to a 35c per Unit distribution declared for the same period last year.

9/11 12:00

Mesabi Trust rises 27.8%

Mesabi Trust is up 27.8%, or $4.66 to $21.42.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。